Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters’ Over-Allotment Option
Zhengye Biotechnology Holding (ZYBT), a Chinese veterinary vaccine manufacturer, announced that underwriters have fully exercised their over-allotment option to purchase an additional 225,000 ordinary shares at $4.00 per share. This follows the company's initial public offering on the Nasdaq Capital Market, which began trading on January 7, 2025.
The total gross proceeds from the IPO, including the over-allotment exercise, amounted to $6.9 million before deducting underwriting discounts and expenses. The company plans to use the proceeds for acquiring vaccine production companies and R&D projects. Kingswood Capital Partners served as the sole book-running manager for the offering.
Zhengye Biotechnology Holding (ZYBT), un produttore cinese di vaccini veterinari, ha annunciato che i sottoscrittori hanno completamente esercitato la loro opzione di sovrallocazione per acquistare ulteriori 225.000 azioni ordinarie a 4,00 $ per azione. Questo segue l'offerta pubblica iniziale della compagnia sul Nasdaq Capital Market, che ha iniziato a essere negoziata il 7 gennaio 2025.
Il totale delle entrate lorde dall'IPO, inclusa l'esercitazione della sovrallocazione, ammonta a 6,9 milioni di dollari prima della deduzione degli sconti e delle spese di sottoscrizione. La compagnia intende utilizzare i proventi per acquisire aziende di produzione di vaccini e progetti di ricerca e sviluppo. Kingswood Capital Partners ha svolto il ruolo di unico manager per l'offerta.
Zhengye Biotechnology Holding (ZYBT), un fabricante chino de vacunas veterinarias, anunció que los suscriptores han ejercido por completo su opción de sobreasignación para comprar 225,000 acciones ordinarias adicionales a 4.00 $ por acción. Esto sigue a la oferta pública inicial de la empresa en el Nasdaq Capital Market, que comenzó a cotizar el 7 de enero de 2025.
Los ingresos brutos totales de la IPO, incluida la ejecución de la sobreasignación, ascendieron a 6.9 millones de dólares antes de deducir los descuentos y gastos de suscripción. La empresa planea utilizar los ingresos para adquirir empresas de producción de vacunas y proyectos de I+D. Kingswood Capital Partners actuó como el único administrador de la oferta.
Zhengye Biotechnology Holding (ZYBT), 중국의 수의학 백신 제조업체, 인수인단이 1주당 4.00 달러에 추가로 225,000주를 구매할 수 있는 초과 배정 옵션을 완전히 행사했다고 발표했습니다. 이는 Nasdaq Capital Market에서 회사의 초기 공개가 시작된 2025년 1월 7일 이후의 일입니다.
초기 공개의 총 총수익은 초과 배정 행사 포함 690만 달러로, 인수 수수료와 비용을 공제하기 전 금액입니다. 회사는 이 자금을 백신 생산 회사 및 연구 개발 프로젝트 인수에 사용할 계획입니다. Kingswood Capital Partners는 이 발행의 유일한 북리딩 매니저로 활동했습니다.
Zhengye Biotechnology Holding (ZYBT), un fabricant chinois de vaccins vétérinaires, a annoncé que les souscripteurs ont entièrement exercé leur option de surallocation pour acheter 225 000 actions ordinaires supplémentaires au prix de 4,00 $ par action. Cela fait suite à l'introduction en bourse de l'entreprise sur le Nasdaq Capital Market, qui a commencé à négocier le 7 janvier 2025.
Le produit brut total de l'IPO, incluant l'exercice de la surallocation, s'est élevé à 6,9 millions de dollars avant déduction des remises et des frais de souscription. L'entreprise prévoit d'utiliser les produits pour acquérir des entreprises de production de vaccins et des projets de R&D. Kingswood Capital Partners a agi en tant que gestionnaire principal unique de l'offre.
Zhengye Biotechnology Holding (ZYBT), ein chinesischer Hersteller von Veterinärvakzinen, gab bekannt, dass die Underwriter ihre Überplatzierungsoption vollständig ausgeübt haben, um zusätzlich 225.000 Stammaktien zu einem Preis von 4,00 $ pro Aktie zu erwerben. Dies folgt auf den Börsengang des Unternehmens am Nasdaq Capital Market, der am 7. Januar 2025 den Handel begann.
Die gesamten Bruttoeinnahmen aus dem IPO, einschließlich der Ausübung der Überplatzierung, beliefen sich auf 6,9 Millionen Dollar, bevor die Underwriting-Rabatte und -Kosten abgezogen wurden. Das Unternehmen plant, die Einnahmen für den Erwerb von Impfstoffproduktionsunternehmen und F&E-Projekten zu verwenden. Kingswood Capital Partners fungierte als alleiniger Book-Running-Manager für die Emission.
- Successfully completed IPO with full exercise of over-allotment option
- Raised $6.9 million in gross proceeds
- Achieved Nasdaq Capital Market listing
- Relatively small IPO size may limit strategic opportunities
- Proceeds subject to reduction from underwriting discounts and expenses
Insights
The successful exercise of the over-allotment option represents a strong vote of confidence in Zhengye Biotechnology's market potential. The additional
The full exercise of the greenshoe option typically indicates robust investor demand and helps stabilize the post-IPO trading price. The company's strategic focus on China's livestock vaccine market positions it well in a growing sector, with the funds earmarked for both inorganic growth through acquisitions and organic expansion via R&D investments. The successful IPO and over-allotment exercise provide Zhengye with both the capital and public company status needed to execute on their expansion strategy.
In simple terms: Think of this like a restaurant's grand opening being so popular that they had to open up their reserve seating area - and those seats got filled too. This extra demand suggests investors are hungry for a piece of China's animal health market and believe in Zhengye's potential to grow in this space.
The Chinese veterinary vaccine market presents significant growth opportunities, driven by increasing meat consumption, stricter food safety regulations and modernization of the livestock industry. Zhengye's successful IPO, including the over-allotment, demonstrates institutional investors' appetite for exposure to this sector. The timing is particularly strategic as China continues to strengthen its agricultural self-sufficiency and food security measures.
The company's dual focus on acquisitions and R&D indicates a balanced growth strategy - seeking both immediate market expansion through M&A while investing in future capabilities through research. For retail investors, this represents one of the few pure-play opportunities to invest in China's veterinary vaccine sector through a U.S.-listed entity.
To break it down simply: Imagine a fast-growing city where more people are buying meat and farmers need to keep their animals healthy. Zhengye makes the "medicine" for these farm animals and big investors just showed they really believe this business will grow. The extra money they raised will help them buy other similar companies and create new animal vaccines.
Jilin, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccine in China, today announced that the underwriter of its initial public offering (the "Offering") have exercised in full their option to purchase an additional 225,000 ordinary shares at a public offering price of
Proceeds from the Offering will be used for acquiring vaccine production companies and conducting R&D projects.
Kingswood Capital Partners, LLC ("Kingswood") acted as the sole book-running manager for the Offering. Hunter Taubman Fischer & Li LLC acted as U.S. securities counsel to the Company, and VCL Law LLP acted as U.S. counsel to Kingswood in connection with the Offering.
A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") (File Number: 333-276436) and was declared effective by the SEC on December 20, 2024. The Offering was made only by means of a prospectus, forming a part of the registration statement. Copies of the prospectus relating to the Offering may be obtained from Kingswood, Attn: Tower 56, 126 E. 56th Street, Suite 22S, New York, NY 10022, or by telephone at +1-732-910-9692. In addition, a copy of the prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 44 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 28 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The operating entity has three GMP veterinary vaccine production floors, including 13 GMP vaccine production lines, one quality examination center, and one animal facility for vaccine development. The operating entity has 49 employees who have over a decade of experience in the veterinary vaccine industry. For more information, please visit the Company’s website: http://ir.jlzybio.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
FAQ
What was the total amount raised in ZYBT's IPO including over-allotment?
When did ZYBT stock begin trading on Nasdaq?
What was the price per share for ZYBT's over-allotment option?
How many additional shares were sold through ZYBT's over-allotment option?
How will ZYBT use the proceeds from its IPO?
